JP5197569B2 - 有機化合物 - Google Patents

有機化合物 Download PDF

Info

Publication number
JP5197569B2
JP5197569B2 JP2009503206A JP2009503206A JP5197569B2 JP 5197569 B2 JP5197569 B2 JP 5197569B2 JP 2009503206 A JP2009503206 A JP 2009503206A JP 2009503206 A JP2009503206 A JP 2009503206A JP 5197569 B2 JP5197569 B2 JP 5197569B2
Authority
JP
Japan
Prior art keywords
alkyl
mmol
dimethyl
imidazol
isochroman
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009503206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009531457A5 (OSRAM
JP2009531457A (ja
Inventor
クリストファー・アダムス
ジュリアン・パピヨン
ゲイリー・マイケル・クサンダー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2009531457A publication Critical patent/JP2009531457A/ja
Publication of JP2009531457A5 publication Critical patent/JP2009531457A5/ja
Application granted granted Critical
Publication of JP5197569B2 publication Critical patent/JP5197569B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2009503206A 2006-03-29 2007-03-27 有機化合物 Expired - Fee Related JP5197569B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78710406P 2006-03-29 2006-03-29
US60/787,104 2006-03-29
PCT/US2007/064974 WO2007117982A2 (en) 2006-03-29 2007-03-27 Organic compounds

Publications (3)

Publication Number Publication Date
JP2009531457A JP2009531457A (ja) 2009-09-03
JP2009531457A5 JP2009531457A5 (OSRAM) 2010-04-22
JP5197569B2 true JP5197569B2 (ja) 2013-05-15

Family

ID=38477291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503206A Expired - Fee Related JP5197569B2 (ja) 2006-03-29 2007-03-27 有機化合物

Country Status (12)

Country Link
US (1) US8153674B2 (OSRAM)
EP (2) EP2001866A2 (OSRAM)
JP (1) JP5197569B2 (OSRAM)
KR (1) KR20080114769A (OSRAM)
CN (1) CN101410389A (OSRAM)
AU (1) AU2007234968A1 (OSRAM)
BR (1) BRPI0709678A2 (OSRAM)
CA (1) CA2644391A1 (OSRAM)
ES (1) ES2442347T3 (OSRAM)
MX (1) MX2008012402A (OSRAM)
RU (1) RU2008142600A (OSRAM)
WO (1) WO2007117982A2 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103880827B (zh) 2004-07-15 2017-01-04 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
KR20090090395A (ko) * 2006-12-18 2009-08-25 노파르티스 아게 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도
US8436035B2 (en) * 2006-12-18 2013-05-07 Novartis Ag Organic compounds
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
CN103958478B (zh) * 2011-11-30 2017-08-01 霍夫曼-拉罗奇有限公司 双环二氢异喹啉‑1‑酮衍生物
MY178867A (en) * 2011-11-30 2020-10-21 Hoffmann La Roche New bicyclic dihydroisoquinoline-1-one derivatives
EP2639212B1 (en) 2012-03-13 2016-03-09 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Enantioselective organic anhydride reactions
MX368093B (es) * 2014-07-24 2019-09-19 Boehringer Ingelheim Int Inhibidores de aldosterona sintasa.
WO2016123275A1 (en) * 2015-01-30 2016-08-04 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
BR112019018700A2 (pt) 2017-03-10 2020-04-07 Embera Neurotherapeutics Inc composições farmacêuticas e seus usos
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
WO2020223267A1 (en) 2019-05-01 2020-11-05 Boehringer Ingelheim International Gmbh (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
KR20240122521A (ko) 2021-12-14 2024-08-12 베링거 인겔하임 인터내셔날 게엠베하 만성 신장 질환 치료용 알도스테론 신타아제 억제제
JP2025540715A (ja) * 2022-11-23 2025-12-16 上▲海▼翰森生物医▲薬▼科技有限公司 ピリジン多環系化合物阻害剤、及びその製造方法と使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904300A (en) * 1987-08-26 1990-02-27 Ciba-Geigy Corp. Imidazole derivatives
DE102004035322A1 (de) * 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen

Also Published As

Publication number Publication date
ES2442347T3 (es) 2014-02-11
JP2009531457A (ja) 2009-09-03
EP2001866A2 (en) 2008-12-17
WO2007117982A2 (en) 2007-10-18
AU2007234968A1 (en) 2007-10-18
MX2008012402A (es) 2008-10-09
KR20080114769A (ko) 2008-12-31
EP2301931A1 (en) 2011-03-30
RU2008142600A (ru) 2010-05-10
CA2644391A1 (en) 2007-10-18
CN101410389A (zh) 2009-04-15
EP2301931B1 (en) 2013-10-16
WO2007117982A3 (en) 2007-12-13
US8153674B2 (en) 2012-04-10
US20090182007A1 (en) 2009-07-16
BRPI0709678A2 (pt) 2011-07-19

Similar Documents

Publication Publication Date Title
JP5197569B2 (ja) 有機化合物
KR102318727B1 (ko) 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도
TWI468401B (zh) 乙炔基衍生物
MX2008002545A (es) Derivados de imidazol condensado para la inhibicion de sintasa de aldosterona y aromatasa.
JP2010513558A (ja) ４−イミダゾリル−１，２，３，４−テトラヒドロキノリン誘導体、およびアルドステロン／１１−ベータ−ヒドロキシラーゼ阻害剤としてのその使用
JP2010513482A (ja) アルドステロンシンターゼ阻害剤としてのイミダゾール類
AU2009247262A1 (en) Amide compound
KR101573998B1 (ko) Mglur5 조절체로서 5-(페닐/피리딘일-에틴일)-2-피리딘/2-피리미딘-카복스아미드
US8415373B2 (en) Isoquinolinone derivatives as NK3 antagonists
KR101576343B1 (ko) 피라졸리딘-3-온 유도체
KR20070087602A (ko) 화합물 및 스테로이드성 수용체 및 칼슘 채널 활성의조절제로서의 조성물
CN104364233B (zh) 芳基乙炔基衍生物
CA2860099A1 (en) Imidazolylketone derivatives asd aldosterone synthase inhibitors
HK1202544B (en) Arylethynyl derivatives
HK1195298B (en) Ethynyl derivatives as mglur5 allosteric modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130205

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160215

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees